No Data
No Data
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments, the tab
Express News | HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)
Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning
Express News | Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
No Data